Your current location is:{Current column} >>Text
If you're high risk, do not wait for updated COVID vaccines, experts say By Reuters
{Current column}3People have watched
Introduction© Reuters. FILE PHOTO: A nurse fills up syringes with the coronavirus disease (COVID-19) vaccines in ...

By Julie Steenhuysen
CHICAGO (Reuters) - People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-generation, Omicron-targeted vaccines expected in the fall, five vaccine experts told Reuters.
In many countries, including the United States, the BA.5 Omicron subvariant of the virus is surging, but current vaccines continue to offer protection against hospitalization for severe disease and death.
And, as the virus evolves, it is not known what version will be widely circulating in the fall or whether new vaccines - expected to target BA.4/5 in the United States and BA.1 in Europe - will be a good match.
“If you need a booster, get it now,” said Dr. John Moore, a professor of microbiology and immunology at Weill Cornell Medical College, who co-wrote an editorial on the subject currently under review.
In the United States, regulators have asked Pfizer Inc (NYSE:PFE) with partner BioNTech SE (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) Inc to develop vaccine boosters that target both the BA.4 and BA.5 Omicron cousins, as well as the original virus. They are expected to be ready by October.
Regulators in Europe, meanwhile, have signaled that they would be willing to use whichever Omicron-based booster is available to Europe soonest, which may well be the one aimed at the BA.1 variant that drove last winter's record surge in infections.
U.S. regulators are hoping an updated vaccine that targets the original strain and an Omicron variant will offer broader protection against future variants, and believe a booster that is closest to the circulating version is valuable.
Given the current surge and people's waning immunity, experts told Reuters the best booster for those at risk is the one at hand.
Only about 30% of people 50 and older who are eligible for a fourth vaccine dose have received one, and fewer than 10% of those aged 50-64, according to the U.S. Centers for Disease Control and Prevention. For those under age 50 or with no major risk factors, a fourth dose has not been approved and there is little support for it among scientific experts.
Moore said the evidence he has seen, including at a June U.S. Food and Drug Administration meeting and since, all suggest that the benefit of a BA.4/5 booster compared to the original vaccine is "negligible" in terms of preventing infection.
“The public should not regard these Omicron-based boosters as some kind of magic bullet that's going to change the face of the pandemic and solve all their problems. It will have a marginal impact compared to the booster we currently have,” he said.
'TOO MANY PEOPLE ARE WAITING'
Dr Eric Topol, a genomics expert and director of the Scripps Research Translational Institute in La Jolla, California, said getting a second booster offers a survival benefit over just one booster that has been documented in five different studies.
“Too many people are waiting when we have really good proof,” he said.
Dr. Bob Wachter, chief of medicine at the University of California, San Francisco, said the evidence is increasingly clear that the longer a person has gone since their last booster, the less protection they have against infection and severe disease.
“There’s a ton of COVID around, and it’s a very infectious agent,” he said.
BA.5 has driven a wave of new cases globally, and now makes up nearly 82% of all U.S. coronavirus infections.
Wachter is not convinced retooled BA.4/5 vaccines will be ready to roll out in two months. “It seems a bit ambitious to me, and even if they hit the timeline, it will probably go to the highest-risk groups first," he said. "I think it’s probably three or four months away for the average person.”
Pfizer told Reuters it has a few million shots of a BA.4/5 vaccine manufactured.
As for the newly authorized Novavax (NASDAQ:NVAX) Inc vaccine, the company has yet to seek approval for its use as a booster.
Moore, who participated in the Novavax clinical trial, said while it is an excellent vaccine, the company's boosters are unlikely to be available soon. Novavax has said it is developing a BA.4/5 booster and is aiming to have it ready by the fourth quarter.
“Whatever is in the pipeline is months away," Topol said. "This is a more virulent, more pathogenic version of the virus and being protected as best you can is smart.”
Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!
Tags:
Related articles
U.S. stocks are falling as investors await CPI report for April By
{Current column}-- U.S. stocks were falling ahead of the consumer price index report for April, due out on Wednesday ...
Read moreFed minutes; Wall Street to close for Independence Day
{Current column}-- Stock markets in the U.S. are due to be closed for the Independence Day holiday on Thursday. Else ...
Read moreOppenheimer boosts S&P 500 price target By
{Current column}Oppenheimer strategists have raised their year-end target price for the to $5,900, up from $5,500, ...
Read more
Popular Articles
- Dow futures rise 15 pts; Walmart earnings, jobless claims in focus By
- Bank of America technical strategists say S&P 500 will hit 6150 By
- Yen hits four
- EVA Markets Operating Beyond Authorized Scope, Avoid at All Costs!
- Factory orders, job openings, Walmart meeting: 3 things to watch By
- Bitcoin price today: Slides to $54k as Mt Gox, German govt dumping fears grow By
Latest articles
-
Stock market today: Dow rallies to wrap up best month since January By
-
Steer Clear of Unregulated Bitrage Markets Platform!
-
HSBC's new gold prices forecast calls for a 12% drop in 2025 By
-
Could Kamala Harris beat Donald Trump in November's presidential race? By Reuters
-
India's milk imports soar as disease hits local cattle stock By Reuters
-
Trump allies rolling out attacks on Harris amid Biden replacement talk